NRXBF
NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of p… Read more
NRXBF (NRXBF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.881x
Based on the latest financial reports, NRXBF (NRXBF) has a cash flow conversion efficiency ratio of -0.881x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.28 Million) by net assets ($1.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
NRXBF - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how NRXBF's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
NRXBF Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NRXBF ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Soosan Heavy I
KO:017550
|
-0.019x |
|
Hengs Technology Co., Ltd.
TWO:4582
|
0.439x |
|
Can Don Hydro Power JSC
VN:SJD
|
-0.003x |
|
Touchstone Exploration Inc
PINK:PBEGF
|
0.068x |
|
FLEURY MICHON INH.EO 305
F:4XZ
|
N/A |
|
Exel Industries
PA:EXE
|
-0.052x |
|
Power Root Bhd
KLSE:7237
|
0.081x |
|
Cineverse Corp.
NASDAQ:CNVS
|
-0.043x |
Annual Cash Flow Conversion Efficiency for NRXBF (2021–2024)
The table below shows the annual cash flow conversion efficiency of NRXBF from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.76 Million | $-4.89 Million | -2.776x | +82.16% |
| 2023-12-31 | $189.00K | $-2.94 Million | -15.561x | -747.60% |
| 2022-12-31 | $2.10 Million | $-3.85 Million | -1.836x | -75.39% |
| 2021-12-31 | $1.18 Million | $-1.23 Million | -1.047x | -- |